RETRACTED ARTICLE: Human induced pluripotent stem cell-derived platelets loaded with lapatinib effectively target HER2+ breast cancer metastasis to the brain

Bhan, Arunoday; Ansari, Khairul I.; Chen, Mike Y

doi:10.1038/s41598-021-96351-2

Cited by 8 publications

(3 citation statements)

References 102 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dual-targeting liposomal co-delivery systems provide another promising strategy for the treatment of patients with advanced EGFRT790M NSCLC and brain metastases, reducing the rate of drug resistance [ 148 ]. Lapatinib-loaded hiPSC platelets delivered to brain metastatic breast cancer cells inhibited the tumor growth and prolonged survival in tumor-bearing mice [ 149 ]. T7 peptide with osimertinib (AZD9291)-loaded intracellular glutathione (GSH)-responsive doxorubicin prodrug self-assembly nanocarriers (T7-DSNPs/9291) was designed as a potential targeted co-delivery system and exhibited anti-NSCLC brain metastasis effects [ 150 ].…”

Section: Microglia Are a Promising Target For The Treatment Of Metast...mentioning

confidence: 99%

The Role of Microglia in Brain Metastases: Mechanisms and Strategies

Zhang

et al. 2024

Aging and disease

View full text Add to dashboard Cite

Brain metastases and related complications are one of the major fatal factors in cancer. Patients with breast cancer, lung cancer, and melanoma are at a high risk of developing brain metastases. However, the mechanisms underlying the brain metastatic cascade remain poorly understood. Microglia, one of the major resident macrophages in the brain parenchyma, are involved in multiple processes associated with brain metastasis, including inflammation, angiogenesis, and immune modulation. They also closely interact with metastatic cancer cells, astrocytes, and other immune cells. Current therapeutic approaches against metastatic brain cancers, including small-molecule drugs, antibody-coupled drugs (ADCs), and immune-checkpoint inhibitors (ICIs), have compromised efficacy owing to the impermeability of the blood-brain barrier (BBB) and complex brain microenvironment. Targeting microglia is one of the strategies for treating metastatic brain cancer. In this review, we summarize the multifaceted roles of microglia in brain metastases and highlight them as potential targets for future therapeutic interventions.

show abstract

Section: Microglia Are a Promising Target For The Treatment Of Metast...mentioning

confidence: 99%

The Role of Microglia in Brain Metastases: Mechanisms and Strategies

Zhang

et al. 2024

Aging and disease

View full text Add to dashboard Cite

show abstract

“…Aside from PRP-generated pEVs, the feasibility of in vitro pEV generation is of great interest. In vitro generation of pEVs from human induced pluripotent stem cells (hiPSC) has been used for treatment of HER2+ breast-to-brain metastasis in a mouse model, although methods to generate the hiPSC-platelets can take up to 20 weeks (Table 1) [171]. Thus, while in vitro pEV generation is worth pursuing, current in vitro generation methods are time consuming.…”

Section: In Vitro Engineering Of Evsmentioning

confidence: 99%

Platelet-Released Factors: Their Role in Viral Disease and Applications for Extracellular Vesicle (EV) Therapy

Ostermeier

Soriano-Sarabia

Maggirwar

2022

IJMS

View full text Add to dashboard Cite

Platelets, which are small anuclear cell fragments, play important roles in thrombosis and hemostasis, but also actively release factors that can both suppress and induce viral infections. Platelet-released factors include sCD40L, microvesicles (MVs), and alpha granules that have the capacity to exert either pro-inflammatory or anti-inflammatory effects depending on the virus. These factors are prime targets for use in extracellular vesicle (EV)-based therapy due to their ability to reduce viral infections and exert anti-inflammatory effects. While there are some studies regarding platelet microvesicle-based (PMV-based) therapy, there is still much to learn about PMVs before such therapy can be used. This review provides the background necessary to understand the roles of platelet-released factors, how these factors might be useful in PMV-based therapy, and a critical discussion of current knowledge of platelets and their role in viral diseases.

show abstract

“…In the case of hiPSCs, they retain the genetic background of the donor [ 363 ]. Both hiPSCs and hESCs have allowed the study of human cells which are not normally accessible to study in the human body (for example, neurons and glial cells of the human CNS) and, therefore, have boosted the possibilities in medical research employing human cell lines, permitting the study of mechanisms of human development [ 363 , 364 ]; in vitro disease modelling, including in cancer research [ 365 , 366 , 367 ]; in the development of assays and platforms for drug screening campaigns [ 355 , 368 , 369 ]; in patient stratification and in the development of cell replacement strategies [ 355 , 363 ]. The pioneer monolayer cultures gave way to organoids, spheroids, organ-on-a-chip approaches and more recently assembloids, which employ single cell types or a multitude of different cellular types [ 355 , 360 , 370 , 371 , 372 , 373 ].…”

Section: Current Challenges and Future Perspectives In Uveal Melanomamentioning

confidence: 99%

Prognostic Biomarkers in Uveal Melanoma: The Status Quo, Recent Advances and Future Directions

Lamas

Martel

Nahon-Estève

et al. 2021

Cancers

View full text Add to dashboard Cite

Uveal melanoma (UM) is the most common malignant intraocular tumour in the adult population. It is a rare cancer with an incidence of nearly five cases per million inhabitants per year, which develops from the uncontrolled proliferation of melanocytes in the choroid (≈90%), ciliary body (≈6%) or iris (≈4%). Patients initially present either with symptoms like blurred vision or photopsia, or without symptoms, with the tumour being detected in routine eye exams. Over the course of the disease, metastases, which are initially dormant, develop in nearly 50% of patients, preferentially in the liver. Despite decades of intensive research, the only approach proven to mildly control disease spread are early treatments directed to ablate liver metastases, such as surgical excision or chemoembolization. However, most patients have a limited life expectancy once metastases are detected, since there are limited therapeutic approaches for the metastatic disease, including immunotherapy, which unlike in cutaneous melanoma, has been mostly ineffective for UM patients. Therefore, in order to offer the best care possible to these patients, there is an urgent need to find robust models that can accurately predict the prognosis of UM, as well as therapeutic strategies that effectively block and/or limit the spread of the metastatic disease. Here, we initially summarized the current knowledge about UM by compiling the most relevant epidemiological, clinical, pathological and molecular data. Then, we revisited the most important prognostic factors currently used for the evaluation and follow-up of primary UM cases. Afterwards, we addressed emerging prognostic biomarkers in UM, by comprehensively reviewing gene signatures, immunohistochemistry-based markers and proteomic markers resulting from research studies conducted over the past three years. Finally, we discussed the current hurdles in the field and anticipated the future challenges and novel avenues of research in UM.

show abstract

RETRACTED ARTICLE: Human induced pluripotent stem cell-derived platelets loaded with lapatinib effectively target HER2+ breast cancer metastasis to the brain

Cited by 8 publications

References 102 publications

The Role of Microglia in Brain Metastases: Mechanisms and Strategies

The Role of Microglia in Brain Metastases: Mechanisms and Strategies

Platelet-Released Factors: Their Role in Viral Disease and Applications for Extracellular Vesicle (EV) Therapy

Prognostic Biomarkers in Uveal Melanoma: The Status Quo, Recent Advances and Future Directions

Contact Info

Product

Resources

About